Malaria endemic countries need to assess efficacy of anti-malarial treatments on a regular basis. Moreover, resistance to artemisinin that is established across mainland South-East Asia represents today a major threat to global health. Monitoring the efficacy of artemisinin-based combination therapies is of paramount importance to detect as early as possible the emergence of resistance in African countries that toll the highest burden of malaria morbidity and mortality.
A WHO standard protocol was used to assess efficacy of the combinations artesunate–amodiaquine (AS–AQ Winthrop®), dihydroartemisinin–piperaquine (DHA–PPQ, Eurartesim®) and artemether–lumefantrine (AM–LM, Coartem®) taken under supervision and respecting pharmaceutical recommendations. The study enrolled for each treatment arm 212 children aged 6–59 months living in Maradi (Niger) and suffering with uncomplicated falciparum malaria. The Kaplan–Meier 42-day PCR-adjusted cure rate was the primary outcome. A standardized parasite clearance estimator was used to assess delayed parasite clearance as surrogate maker of suspected artemisinin resistance.
No early treatment failures were found in any of the study treatment arms. The day-42 PCR-adjusted cure rate estimates were 99.5, 98.4 and 99.0% in the AS–AQ, DHA–PPQ and AM–LM arms, respectively. The reinfection rate (expressed also as Kaplan–Meier estimates) was higher in the AM–LM arm (32.4%) than in the AS–AQ (13.8%) and the DHA–PPQ arm (24.9%). The parasite clearance rate constant was 0.27, 0.26 and 0.25 per hour for AS–AQ, DHA–PPQ and AM–LM, respectively.
All the three treatments evaluated largely meet WHO criteria (at least 95% efficacy). AS–AQ and AL–LM may continue to be used and DHA–PPQ may be also recommended as first-line treatment for uncomplicated falciparum malaria in Maradi. The parasite clearance rate were consistent with reference values indicating no suspected artemisinin resistance. Nevertheless, the monitoring of anti-malarial drug efficacy should continue.
Trial registration details Registry number at ClinicalTrial.gov: NCT01755559
WHO. World malaria report 2016. Geneva: World Health Organization; 2016.
Direction de la lutte contre la maladie et les endémies—Division des maladies transmissibles. Politique Nationale de Lutte contre le Paludisme. Niamey; 2008 (in French).
Salissou A, Halima BM, Abani M, Adehossi E, Daou M, Boureima S, et al. Efficacité et tolérance de l’association artéméther luméfantrine dans le traitement du paludisme simple à Plasmodium falciparum au Niger. Journal de la Recherche Scientifique de l’Université de Lomé. 2012;14:79–84 (in French).
Laminou IM, Fatouma S, Maman D, Boubacar H, Maazou A, Zamanka H, et al. Comparison of the efficacy and safety of artemether–lumefantrine with artesunate–amodiaquine in Niger. Mali Med. 2016;31:1–7 (in French).
Laminou IM, Lamine MM, Mahamadou B, Ascofaré OM, Dieye A. Polymorphism of pfk13-propeller in Niger: detection of novel mutations. Journal of Advances in Medicine and Medical Research. 2017;22:1–5. CrossRef
European Medicines Agency. Eurartesim. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001199/WC500118117.pdf. Accessed 6 Dec 2011.
WHO. Antimalarial treatment policy. In: Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010. p. 8–9.
WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
WorldWide Antimalarial Resistance Network (WWARN). Methodology for the WWARN Parasite Clearance Estimator. 2012. http://www.wwarn.org/sites/default/files/attachments/documents/WWARN-Parasite-Clearance-Estimator-PCE-Methodology.pdf. Accessed 20 May 2015.
ICH Expert Working Group. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). 1996. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
ICH Expert Working Group. ICH Harmonised Tripartite Guideline. Structure and Content of Clinical Study Reports E3. 1995. http://solyur.ru/images/docs-world/ICH_E3.pdf.
Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin–piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother. 2008;52:1052–61. CrossRefPubMedPubMedCentral
Karunakara U. Data sharing in a humanitarian organization: the experience of Médecins Sans Frontières. PLoS Med. 2013;10(12):e1001562. https://doi.org/10.1371/journal.pmed.1001562. CrossRefPubMedPubMedCentral
- Efficacy of artesunate–amodiaquine, dihydroartemisinin–piperaquine and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger
Lynda Woi Messe
Ibrahim Maman Laminou
Martin de Smet
Odile Ouwe Missi Oukem-Boyer
Ogobara K. Doumbo
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II